Keeping Track: FDA Delays Elagolix, Mylan Eyes For Neulasta Biosimilar Approval, And Duvelisib Gets Priority Review

15 Apr 2018

• By Michael Cipriano and Jessica Merrill

The latest drug development news and highlights from our US FDA Performance Tracker.

More from Biosimilars